The Ministry of Health has allowed the third part of testing of the Epivaccorona-N vaccine for individuals over 60 years of age.
This is an “open study of the safety, tolerability, reactogenicity and immunogenicity of the peptide antigen-based Epivaccorona-N vaccine for the prevention of COVID-19 in volunteers over the age of 60,” famous within the register of permits for medical trials.
The trials will contain senior residents who’ve had the an infection six and 12 months in the past or had been vaccinated six months in the past.
Doctors will research the opportunity of a single (booster) utility of the Epivaccorona-N vaccine after the sickness.
The exams will final till December 30, 300 individuals will participate in them.
The Epivaccorona-N vaccine was developed by the Vector Center of Rospotrebnadzor, registered by the Ministry of Health on August 26, 2021.
The head of the Vector middle, Rinat Maksyutov, stated there have been no necessary differences between “Epivaccorona-N” and the previously developed “Epivaccorona”. Vaccines differ in technological options of manufacturing, which has change into the principle motive for the necessity for brand new medical trials to resolve manufacturing issues.